Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | COPS5 | Q92905 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535765 | 0.87 | L3MBTL1 (0.56) | FBP1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL31661345 | 0.86 | FBP1 (0.72) | FBP1ALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL2442951 | 0.83 | KDM4E (0.51) | FBP1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL2400726 | 0.83 | FBP1 (0.48) | FBP1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL5217772 | 0.81 | FBP1 (0.58) | FBP1ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL4166061 | 0.80 | KDM4E (0.59) | FBP1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL4130111 | 0.80 | FBP1 (1.00) | FBP1ALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL3066792 | 0.79 | KDM4E (0.48) | FBP1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL30200863 | 0.78 | FBP1 (0.46) | FBP1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL3100377 | 0.75 | ALDH1A1 (0.47) | FBP1ALDH1A1KDM4ESMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795289-B2 | Use of acylaminothiazole derivatives as therapeutic agents | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | disclosed |
| US-20080051436-A1 | Use of Acylaminothiazole Derivatives as Therapeutic Agents | SANOFI-AVENTIS (FR) | 2008-02-28 | — | — | US | disclosed |
| US-7291636-B2 | Acylaminothiazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-06 | — | — | US | disclosed |
| US-20050182104-A1 | Acylaminothiazole derivatives, preparation and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051436-A1 | Use of Acylaminothiazole Derivatives as Therapeutic Agents | BACE1, BACE2, ATG4A | FBP1 3627/4885ALDH1A1 1460/4885KDM4E 1431/4885 |
| US-20050182104-A1 | Acylaminothiazole derivatives, preparation and therapeutic use thereof | BACE1, APP, BACE2 | FBP1 3388/4885ALDH1A1 1639/4885KDM4E 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.